Catalys Pacific, a Japanese life sciences venture capital firm, has just launched its first fund.
Led by BT Slingsby, Takeshi Takahashi, and Bill Watt, Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences. Its mission is to focus on providing healthcare solutions for patients worldwide through the creation of and investment in bioventure companies. The firm, which maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in Seattle, Washington, leeverages its networks in academia, biotech, venture capital and the pharmaceutical industry.
Its Strategic Partners are:
– Chugai Pharmaceutical Co., Ltd.,
– Eisai Co., Ltd.,
– SoftBank Group Corp.,
– Takeda Pharmaceutical Company Limited, and
– Celgene Corporation.
Venture capital partners include:
– Domain Associates, and
– Frazier Healthcare Partners.